| abstract |
The present invention discloses a method for treating psychosomatic disorders, depression and neuropsychiatric disorders in animals, including humans, such as anxiety, depression, insomnia, schizophrenia, epilepsy, convulsions and chronic pain. Administration of a suitable attractin inhibitor reduces the activity of the enzyme atractin or its isoform in the brain of mammals, resulting in reduced degradation of neuropeptide Y (NPY) and similar substrates. Such treatment will reduce or delay the decrease in NPY (1-36) levels in functionally active neurons. Increased stability of endogenous NPY (1-36) results in prolonged NPY activity, which results in particularly functionally active NPY YI receptor activity, thereby antidepressant, anxiolytic, analgesic, antihypertensive And other neurological effects are promoted. |